Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis

References

• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007.
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160S–198S. doi: 10.1378/chest.08-0670.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi: 10.1056/NEJMoa1310907.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.
   PubMed Web of Science ®Google Scholar
• Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–2106. doi: 10.1111/bcp.13299.
   PubMed Web of Science ®Google Scholar
• Maura G, Billionnet C, Drouin J, et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016. BMJ Open. 2019;9(4):e026645. doi: 10.1136/bmjopen-2018-026645.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Pradaxa – summary of product characteristics; 2018 [accessed 2019 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Xarelto – summary of product characteristics; 2018 [accessed 2019 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Apixaban – summary of product characteristics; 2018 [accessed 2019 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Edoxaban – summary of product characteristics; 2018 [accessed 2019 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf
   Google Scholar
• Cohen AT, Hill NR, Luo X, et al. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants. Int J Cardiol. 2018;269:174–181. doi: 10.1016/j.ijcard.2018.06.114.
   PubMed Web of Science ®Google Scholar
• Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384–1392. doi: 10.1161/CIRCULATIONAHA.119.044059.
   PubMed Web of Science ®Google Scholar
• Patel SM, Braunwald E, Steffel J, et al. Efficacy and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and body weight: an individual patient data meta-analysis of four randomized clinical trials of 58 464 patients with atrial fibrillation. Circulation. 2024;149(12):932–943. doi: 10.1161/CIRCULATIONAHA.123.066279.
   PubMed Web of Science ®Google Scholar
• Lawal OD, Aronow HD, Shobayo F, et al. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study. Circulation. 2023;147(10):782–794. doi: 10.1161/CIRCULATIONAHA.122.060687.
   PubMed Web of Science ®Google Scholar
• Hydes TJ, Lip GYH, Lane DA. Use of direct-acting oral anticoagulants in patients with atrial fibrillation and chronic liver disease. Circulation. 2023;147(10):795–797. doi: 10.1161/CIRCULATIONAHA.122.063195.
   PubMed Web of Science ®Google Scholar
• Gilbert C, White I, Marder VJ, et al. Overview of basic coagulation and fibrinolysis. In: Marder VJ, editor. Hemostasis and thrombosis basic principles and clinical practice. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2013.
   Google Scholar
• Posma JJ, Posthuma JJ, Spronk HM. Coagulation and non-coagulation effects of thrombin. J Thromb Haemost. 2016;14(10):1908–1916. doi: 10.1111/jth.13441.
   PubMed Web of Science ®Google Scholar
• Crawley JT, Zanardelli S, Chion CK, et al. The central role of thrombin in hemostasis. J Thromb Haemost. 2007;5 Suppl 1:95–101. doi: 10.1111/j.1538-7836.2007.02500.x.
   PubMed Web of Science ®Google Scholar
• Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res. 1982;25(1–2):51–70. doi: 10.1016/0049-3848(82)90214-6.
   PubMed Web of Science ®Google Scholar
• Pieters M, Undas A, Marchi R, et al. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost. 2012;10(10):2179–2181. doi: 10.1111/j.1538-7836.2012.04883.x.
   PubMedGoogle Scholar
• Rooth E, Wallen NH, Blombäck M, et al. Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke. Thromb Res. 2011;127(1):51–56. doi: 10.1016/j.thromres.2010.09.011.
   PubMed Web of Science ®Google Scholar
• Drabik L, Wołkow P, Undas A. Fibrin clot permeability as a predictor of stroke and bleeding in anticoagulated patients with atrial fibrillation. Stroke. 2017;48(10):2716–2722. doi: 10.1161/STROKEAHA.117.018143.
   PubMed Web of Science ®Google Scholar
• Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009;114(19):4272–4278. doi: 10.1182/blood-2009-05-222380.
   PubMed Web of Science ®Google Scholar
• Undas A, Szułdrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008;196(2):551–557. doi: 10.1016/j.atherosclerosis.2007.05.028.
   PubMed Web of Science ®Google Scholar
• Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76(4):535–540. doi: 10.1055/s-0038-1650618.
   PubMed Web of Science ®Google Scholar
• Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2567–2573. doi: 10.1161/01.ATV.0000241589.52950.4c.
   PubMed Web of Science ®Google Scholar
• Ząbczyk M, Blombäck M, Majewski J, et al. Assays of fibrin network properties altered by VKAs in atrial fibrillation – importance of using an appropriate coagulation trigger. Thromb Haemost. 2015;113(4):851–861. doi: 10.1160/TH14-07-0591.
   PubMed Web of Science ®Google Scholar
• He S, Blombäck M, Bark N, et al. The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis. Thromb Haemost. 2010;103(5):1076–1084. doi: 10.1160/TH09-05-0306.
   PubMed Web of Science ®Google Scholar
• Blombäck M, He S, Bark N, et al. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol. 2011;152(6):758–765. doi: 10.1111/j.1365-2141.2010.08546.x.
   PubMed Web of Science ®Google Scholar
• Ząbczyk M, Majewski J, Karkowski G, et al. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3 days of treatment: relation to coagulation factors and thrombin generation. Thromb Res. 2015;136(4):832–838. doi: 10.1016/j.thromres.2015.08.007.
   PubMed Web of Science ®Google Scholar
• He S, Johnsson H, Zabczyk M, et al. A fibrinogen concentrate haemocomplettan (Riastap) or a factor XIII concentrate fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor. Br J Haematol. 2013;160(6):806–816. doi: 10.1111/bjh.12189.
   PubMed Web of Science ®Google Scholar
• Janion-Sadowska A, Natorska J, Siudut J, et al. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban. Thromb Haemost. 2017;117(9):1739–1749. doi: 10.1160/TH17-01-0060.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32(5–6):249–253. doi: 10.1159/000073575.
   PubMedGoogle Scholar
• Rooth E, Sobocinski-Doliwa P, Antovic J, et al. Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke. Scand J Clin Lab Invest. 2013;73(7):576–584. doi: 10.3109/00365513.2013.826817.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Folsom AR, Heckbert SR, et al. Peak thrombin generation and subsequent venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE) study. J Thromb Haemost. 2009;7(10):1639–1648. doi: 10.1111/j.1538-7836.2009.03561.x.
   PubMed Web of Science ®Google Scholar
• Skeppholm M, Kallner A, Malmqvist K, et al. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res. 2011;128(5):483–489. doi: 10.1016/j.thromres.2011.03.011.
   PubMed Web of Science ®Google Scholar
• Sumaya W, Wallentin L, James SK, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J. 2018;39(13):1078–1085. doi: 10.1093/eurheartj/ehy013.
   PubMed Web of Science ®Google Scholar
• Ammollo CT, Semeraro F, Incampo F, et al. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010;8(4):790–798. doi: 10.1111/j.1538-7836.2010.03739.x.
   PubMed Web of Science ®Google Scholar
• Lisman T, de Groot PG, Meijers JC, et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102–1105. doi: 10.1182/blood-2004-08-3253.
   PubMed Web of Science ®Google Scholar
• Carter AM, Cymbalista CM, Spector TD, et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007;27(12):2783–2789. doi: 10.1161/ATVBAHA.107.153221.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411–2420. doi: 10.1016/j.jacc.2017.09.024.
   PubMed Web of Science ®Google Scholar
• McFarland CP, Lind SE. Thrombin generation biomarkers decline with parenteral anticoagulation–an overlooked means of anticoagulation monitoring? Clin Appl Thromb Hemost. 2018;24(5):708–717. doi: 10.1177/1076029617746506.
   PubMed Web of Science ®Google Scholar
• Lippi G, Cervellin G, Franchini M, et al. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Thromb Thrombolysis. 2010;30(4):459–471. doi: 10.1007/s11239-010-0460-x.
   PubMed Web of Science ®Google Scholar
• He S, Cao H, Antovic A, et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis. 2005;16(1):61–67. doi: 10.1097/00001721-200501000-00010.
   PubMed Web of Science ®Google Scholar
• Dey S. A new rapid air-drying technique for scanning electron microscopy using tetramethylsilane: application to mammalian tissue. Cytobios. 1993;73:17–23.
   PubMedGoogle Scholar
• Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013;69(11):1875–1881. doi: 10.1007/s00228-013-1550-4.
   PubMed Web of Science ®Google Scholar
• Skeppholm M, Al-Aieshy F, Berndtsson M, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015;136(1):148–153. doi: 10.1016/j.thromres.2015.04.030.
   PubMed Web of Science ®Google Scholar
• Al-Aieshy F, Malmström RE, Antovic J, et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72(6):671–679. doi: 10.1007/s00228-016-2060-y.
   PubMed Web of Science ®Google Scholar
• Helin TA, Lemponen M, Hjemdahl P, et al. From laboratory to clinical practice: dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res. 2015;136(1):154–160. doi: 10.1016/j.thromres.2015.04.032.
   PubMed Web of Science ®Google Scholar
• Wagenvoord RJ, Deinum J, Elg M, et al. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost. 2010;8(6):1281–1289. doi: 10.1111/j.1538-7836.2010.03822.x.
   PubMed Web of Science ®Google Scholar
• Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127(5):457–465. doi: 10.1016/j.thromres.2011.01.001.
   PubMed Web of Science ®Google Scholar
• Samama MM, Le Flem L, Guinet C, et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost. 2007;5(12):2554–2556. doi: 10.1111/j.1538-7836.2007.02753.x.
   PubMed Web of Science ®Google Scholar
• Bloemen S, Zwaveling S, Douxfils J, et al. The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. Thromb Res. 2018;171:160–166. doi: 10.1016/j.thromres.2018.10.005.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW, Etexilate D. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436–1450. doi: 10.1161/CIRCULATIONAHA.110.004424.
   PubMed Web of Science ®Google Scholar
• He S, Cao H, Thålin C, et al. The clotting trigger is an important determinant for the coagulation pathway in vivo or in vitro-inference from data review. Semin Thromb Hemost. 2021;47(1):63–73. doi: 10.1055/s-0040-1718888.
   PubMedGoogle Scholar
• Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(8):1008–1020. doi: 10.1055/a-1450-8178.
   PubMedGoogle Scholar
• Tripodi A, Ageno W, Ciaccio M, et al. Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018;16(5):462–470. doi: 10.2450/2017.0124-17.
   PubMed Web of Science ®Google Scholar
• Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(5):594–622. doi: 10.1016/j.jacc.2020.04.053.
   PubMed Web of Science ®Google Scholar
• Kopytek M, Zabczyk M, Natorska J, et al. Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism. J Physiol Pharmacol. 2020;71(1):47–53. doi: 10.26402/jpp.2020.1.03.
   Web of Science ®Google Scholar
• Herrmann R, Thom J, Wood A, et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014;111(5):989–995. doi: 10.1160/TH13-07-0607.
   PubMed Web of Science ®Google Scholar
• Dinkelaar J, Patiwael S, Harenberg J, et al. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med. 2014;52(11):1615–1623. doi: 10.1515/cclm-2014-0307.
   PubMed Web of Science ®Google Scholar
• Helin TA, Lemponen M, Lassila R, et al. Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the calibrated automated thrombogram. Res Pract Thromb Haemost. 2021;5(3):439–446. doi: 10.1002/rth2.12497.
   PubMed Web of Science ®Google Scholar
• Pfrepper C, Metze M, Siegemund A, et al. Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system. Res Pract Thromb Haemost. 2020;4(4):619–627. doi: 10.1002/rth2.12340.
   PubMed Web of Science ®Google Scholar
• Giesen PLA, Gulpen AJW, van Oerle R, et al. Calibrated automated thrombogram II: removing barriers for thrombin generation measurements. Thromb J. 2021;19:60.
   PubMed Web of Science ®Google Scholar
• Kopatz WF, Brinkman HJM, Meijers JCM. Use of DOAC stop for elimination of anticoagulants in the thrombin generation assay. Thromb Res. 2018;170:97–101. doi: 10.1016/j.thromres.2018.08.014.
   PubMed Web of Science ®Google Scholar
• Artang R, Anderson M, Riley P, et al. Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. Res Pract Thromb Haemost. 2017;1(2):194–201. doi: 10.1002/rth2.12044.
   PubMed Web of Science ®Google Scholar
• Königsbrügge O, Weigel G, Quehenberger P, et al. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Clin Exp Med. 2018;18(3):325–336. doi: 10.1007/s10238-018-0490-9.
   PubMed Web of Science ®Google Scholar
• Collet JP, Soria J, Mirshahi M, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood. 1993;82(8):2462–2469. doi: 10.1182/blood.V82.8.2462.2462.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Incampo F, Ammollo CT, et al. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thromb Res. 2016;138:22–29. doi: 10.1016/j.thromres.2015.12.023.
   PubMed Web of Science ®Google Scholar
• Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. Am J Hematol. 2019;94(7):833–839. doi: 10.1002/ajh.25482.
   PubMed Web of Science ®Google Scholar
• Siegbahn A, Oldgren J, Andersson U, et al. D-dimer and factor VIIa in atrial fibrillation – prognostic values for ­cardiovascular events and effects of anticoagulation therapy. A RE-LY ­substudy. Thromb Haemost. 2016;115(5):921–930. doi: 10.1055/s-0037-1615530.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944. doi: 10.1161/STROKEAHA.118.020232.
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402. doi: 10.1001/archinternmed.2011.1666.
   PubMed Web of Science ®Google Scholar
• Artang R, Rome E, Nielsen JD, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013;112(12):1973–1979. doi: 10.1016/j.amjcard.2013.08.027.
   PubMed Web of Science ®Google Scholar